

**Minnesota Department of Human Services
DUR Board Meeting**

May 10, 2023

Members Present

Amanda Elliot, Pharm.D., Arnes Huskic, M.D., Daniel Jude, Pharm.D., Karen Pedersen, PharmD., and Ann Philbrick, PharmD.

DHS Staff Present

Mary Beth Reinke, PharmD., DUR Coordinator.

Other Attendants

Ariane Casey, PharmD. Kepro, Cory Chambliss, Kepro, and Alena Mitchell, PharmD, Kepro.

Public Comments: There were no public comments.

Approval of Minutes: Minutes from the February 8, 2023 meeting were approved.

Old business:

The updated status of the two recent population-based interventions was: 1) SUPPORT Act was mailed February 2, 2023, 2) Psychotropic Drugs in Youth was mailed March 3, 2023, and 3) Non-Adherence was mailed April 11, 2023.

New business:

SUPPORT Act #2 2022 Evaluation

Pre-intervention baseline period, February 3, 2022, consisted of 750 letters to 750 targeted prescribers and 421 distinct targeted patients. A patient could have more than one clinical indicators. In the post-intervention period, there were 372 patients. The overall occurrences on clinical indicators decreased by 51.7%. The 6-month total savings was \$136,726.05 which was \$61.26 savings per recipient per month.

Singular (montelukast) Black Box Warning Evaluation

Pre-intervention baseline period, December 15, 2021, to June 13, 2022, consisted of 1,385 letters to 1,385 targeted prescribers and 1,517 distinct targeted patients. A patient could have more than one clinical indicators. In the post-intervention period, there were 1,299 patients. Overall occurrences on clinical indicators decreased by 46.82%. The 6-month total savings was \$91,619.57 which was \$11.76 savings per recipient per month. There was improvement in clinical edits as well as cost savings.

Psychotropics in Adults Evaluation 2021

Pre-intervention baseline period, October 9, 2021, to April 7, 2022 consisted of 3,018 letters to 1,385 targeted prescribers and 3,462 distinct targeted patients. A patient could have more than one clinical indicators. In the post-intervention period, there were 2,861 patients. Overall occurrences on clinical indicators decreased by 38.35%. The 6-month total savings was \$445,927.34 which was \$25.98 savings per recipient per month. There was improvement in clinical edits as well as cost savings.

Psychotropics in Adults Intervention 2023

The DUR Board approved profile review criteria for 1) Polypharmacy of 3 or more psychotropics medications concurrently for at least 30 days in the last 60 days and 2) two or more oral second generation antipsychotics (SGA) for at least 30 days in the last 60 days. Criteria and special mailing format was approved for lack of SGA blood glucose monitoring within the last year with 3,057 occurrences and lack of SGA lipid monitoring within the last year with 1,452 occurrences.

The next DUR Board meeting will be August 9, 2023. The meeting was adjourned.